Date: Thu, 20 Nov 1997 21:06:45 GMT Server: Apache-SSL-US/1.0.5+1.0+1.1.1 Content-type: text/html Content-length: 34504 Last-modified: Thu, 20 Nov 1997 18:50:50 GMT

News Release Menu

[Financials | Film Products | Alum. Extrusions | Technology | SEC Filings | Stock Quote | E-Mail]


FOR IMMEDIATE RELEASE TREDEGAR TO BUILD PLASTIC FILMS PLANT IN POLAND

RICHMOND, Va., Nov. 19, 1997 -- Tredegar Industries (NYSE:TG) announced that its Film Products division will build a manufacturing facility in Poland to meet growing demand for its products throughout Europe and in Russia. The new plant, which is expected to begin production in the first quarter of 1999, will make specialty plastic films used primarily in personal hygiene products. The plant will be located in Lodz or Warsaw. Final site selection is expected by the end of 1997.

Upon completion, the new plant will become Tredegar’s fifth manufacturing facility located outside the U.S. The company currently operates plants in the Netherlands, Brazil and Argentina. A new plant in China, announced earlier this year, is expected to begin production in the first half of 1998. Tredegar has six plants and a technical center in the U.S. Anthony J. Rinaldi, president of Tredegar Film Products, said: “The establishment of a manufacturing presence in Poland is a logical extension of our globalization strategy. Since 1989, our plant in Kerkrade, the Netherlands, has been able to meet steadily growing demand from European markets. This new facility will increase penetration of markets throughout Europe and in Russia.”

Tredegar Film Products is a major supplier of embossed and permeable films for disposable personal products. It also produces films for packaging, medical, industrial, agricultural and landscaping markets. Tredegar Industries is a manufacturer of plastics and aluminum extrusions. The company also has interests in drug discovery and other emerging technologies.

[Top of Page]


TREDEGAR BOARD DECLARES DIVIDEND

RICHMOND, Va., Nov. 19, 1997 -- The board of directors of Tredegar Industries (NYSE:TG) declared a quarterly dividend of nine cents per share on the company's common stock. The dividend is payable on January 1, 1998, to shareholders of record on December 12, 1997. Tredegar Industries is a Richmond-based manufacturer of plastics and aluminum extrusions with interests in drug discovery and other emerging technologies.

[Top of Page]


STRENGTH IN MANUFACTURING AND TECHNOLOGY SEGMENTS PUSHES TREDEGAR EARNINGS TO RECORD LEVELS

RICHMOND, Va., Oct. 13, 1997 -- Strong operating earnings and investment gains boosted Tredegar Industries’ (NYSE:TG) third-quarter net income to $15.1 million ($1.14 per share), up from $10.7 million (82 cents per share) in 1996. Excluding investment gains and unusual items, net income was $13.0 million (98 cents per share), up from $8.9 million (69 cents per share) in 1996.

Third-quarter sales were $155.1 million, up from $129.4 million in 1996.

The improvement in third-quarter operating earnings was driven by continued strength in the company’s aluminum and plastics businesses, where profits rose 34 percent and 28 percent, respectively, compared with the year-ago period. Operating results also improved due to higher contract research revenues at Molecumetics, Tredegar’s drug development subsidiary.

Third-quarter results include a net after-tax gain of $2.1 million (16 cents per share) related to the sale of equity investments in the company’s technology segment. Through the first nine months of 1997, technology-related investment gains totaled $6.2 million after taxes (47 cents per share). On September 30, the cost basis of Tredegar’s technology investments was $18.2 million, up from $6 million at the end of 1996. The estimated fair value of these investments on September 30 was $34 million.

Net income for the first nine months of 1997 was $42.4 million ($3.23 per share), up from $35.8 million ($2.74 per share) in 1996. Excluding investment gains and unusual items, year-to-date earnings were $34.8 million ($2.65 per share) versus $25.9 million ($1.99 per share) in 1996. Year-to-date sales totaled $433.4 million, up from $397.1 million in 1996.

In addition to technology-related investment gains, year-to-date earnings for 1997 include an after-tax gain of $1.4 million (11 cents per share) related to the sale of preferred stock received in connection with last year’s divestiture of a molded plastics subsidiary.

Last year’s third-quarter earnings include a technology-related investment gain of $1.4 million after taxes (10 cents per share) and an after-tax gain of $420,000 (three cents per share) related to unusual items. Results for the first nine months of 1996 include technology-related investment gains of $1.4 million after taxes (10 cents per share) and a net after-tax gain of $8.5 million (65 cents per share) related primarily to divestitures.

Tredegar Industries is a manufacturer of plastics and metal products with interests in drug discovery and other emerging technologies.

[Top of Page]


TREDEGAR’S MOLECUMETICS SUBSIDIARY, TEIJIN TO COLLABORATE ON ANTI-COAGULANT DRUG RESEARCH

RICHMOND, Va., Sep. 10, 1997 -- Molecumetics Ltd. and Teijin Limited announced today the signing of a research and licensing collaboration aimed at the development of new therapeutic drugs for treatment of a variety of blood clotting disorders. The joint effort will focus on developing Molecumetics’ orally active inhibitors of thrombin, a key protease in the blood clotting process. Molecumetics’ oral thrombin inhibitors are the most advanced compounds generated to date by the company’s various drug lead development programs. The company’s scientists have identified a family of potent drug lead compounds that have proven to be effective when tested in primates. The agreement with Teijin is Molecumetics’ second research partnership in the blood clotting area.

In May of this year, Molecumetics and Asahi Chemical Industry Co., Ltd., agreed to collaborate on the development of Molecumetics’ orally active inhibitors of factor VIIa, another protease involved in the blood coagulation process. Under the terms of the agreement with Teijin, Molecumetics will be responsible for the optimization of its drug lead compounds. Both companies will perform preclinical studies, while Teijin will be responsible for clinical development, regulatory approval and marketing of the compounds in Japan and other Asian markets. Molecumetics will receive initial fees, research funding, milestone payments based on clinical progress, and royalties on sales of products in Japan and Asia. Molecumetics retains all rights to the compounds in the United States and Europe.

John D. Gottwald, Tredegar’s president and chief executive officer, said: “The agreement with Teijin is an important step in our efforts to demonstrate the value of Molecumetics’ technology. It represents our second collaboration in the anti-coagulant area and reinforces our belief that our technology is viable from both a scientific and commercial perspective. We’re actively seeking new opportunities to build a portfolio of drug development partnerships that will provide additional research funding and potential royalties.” Teijin Limited, based in Osaka, Japan, is a leading global manufacturer of synthetic fibers, textiles, films and healthcare products including pharmaceuticals. Teijin entered the pharmaceutical business in 1974. The company’s 1996 revenues were approximately $6 billion.

Molecumetics is a drug discovery company dedicated to the identification of orally active preclinical lead compounds for clinical development by the pharmaceutical and biotechnology industries. Compounds currently under development at Molecumetics are designed to treat heart disease, blood coagulation disorders, inflammatory diseases such as asthma and arthritis, and cancer. The company, headquartered in the Seattle area, is owned by Tredegar Industries of Richmond, Virginia (NYSE:TG). Tredegar Industries is a manufacturer of plastics and aluminum extrusions and has interests in drug discovery and other emerging technologies. Tredegar’s 1996 sales totaled $523.6 million.

[Top of Page]


TREDEGAR BOARD RAISES DIVIDEND

RICHMOND, Va., Aug. 27, 1997 -- The board of directors of Tredegar Industries (NYSE:TG) voted today to raise the quarterly cash dividend on the company’s common stock from eight cents to nine cents per share. The dividend is payable on October 1, 1997, to shareholders of record on September 12, 1997. Tredegar Industries is a Richmond-based manufacturer of plastics and aluminum extrusions with interests in drug discovery and other emerging technologies.

[Top of Page]


STRENGTH IN CORE BUSINESSES, INVESTMENT GAINS PUSHES TREDEGAR EARNINGS TO RECORD LEVELS

RICHMOND, Va., Jul. 14, 1997 -- Driven by record profits in core manufacturing operations and investment gains, Tredegar Industries’ (NYSE:TG) second-quarter net income was $16,347,000 or $1.25 cents per share, up from $8,673,000 or 66 cents per share in 1996. Excluding investment gains and nonrecurring items, this year’s second-quarter net income from operations was $12,044,000 or 92 cents per share. The increased operating income was due to higher profits in the company’s core aluminum and plastics businesses, where profits rose 45 percent and 19 percent, respectively, versus last year’s second quarter. Second-quarter sales were $144,969,000, up from $126,331,000 in 1996. Tredegar’s reported earnings of $1.25 per share include a net after-tax gain of $2.9 million or 22 cents per share related to the sale of equity investments in the company’s technology segment. The $1.25 per share figure also includes a nonrecurring after-tax gain of $1.4 million or 11 cents per share related to the sale of preferred stock received in connection with last year’s divestiture of a molded plastics subsidiary.

John D. Gottwald, Tredegar’s president and chief executive officer, said: “Everything seemed to come together for Tredegar this quarter. Our plastic films business continued its strong and steady performance, while profits in aluminum once again exceeded our expectations. On top of this strength in core operations, the equity investments in our technology segment continued to generate high rates of return and our Molecumetics subsidiary signed a drug development partnership with Asahi Chemical, an important first step in demonstrating the value of its technology.”

For the first six months of 1997, Tredegar’s reported net income was $27,301,000 or $2.08 per share compared with $25,020,000 or $1.92 per share in the first half of 1996. Excluding investment gains and nonrecurring items, year-to-date net income was $21,792,000 or $1.66 per share versus $16,961,000 or $1.30 per share in 1996. Sales for the first half of 1997 were $278,314,000, up from $267,718,000 in 1996. Year-to-date results for 1997 include after-tax gains totaling $4.1 million or 31 cents per share related to the sale of equity investments in the company’s technology segment, and an after-tax gain of $1.4 million or 11 cents per share generated by the sale of preferred stock related to last year’s divestiture of a molded plastics subsidiary. Results for the first six months of 1996 include a net after-tax gain of $8.1 million or 62 cents per share related to divestitures. Tredegar Industries is a manufacturer of plastics and metal products with interests in drug discovery and other emerging technologies.

[Top of Page]


TREDEGAR COMPLETES PURCHASE OF ALUMINUM PLANT FROM REYNOLDS METALS

RICHMOND, Va., May 30, 1997 -- Tredegar Industries (NYSE:TG) announced that its William L. Bonnell subsidiary has purchased an aluminum extrusions plant in El Campo, Texas, from Richmond-based Reynolds Metals Company (NYSE:RLM). The El Campo facility, which employs 233 people and had sales of about $45 million in 1996, extrudes and fabricates products used primarily in transportation, electrical and consumer durables markets. Tredegar’s Bonnell subsidiary employs approximately 1,300 people at extrusion plants in Newnan, Ga., Carthage, Tenn., and Kentland, Ind., and had sales of $219 million in 1996. Bonnell’s primary markets include building and construction, transportation and consumer durables. John D. Gottwald, Tredegar’s president and chief executive officer, said: “The El Campo acquisition should provide growth in our aluminum business by enabling us to take our competitive strengths -- high quality, low-cost manufacturing and superior customer service -- into new markets, particularly in the southwestern United States.” Tredegar Industries is a manufacturer of plastics and aluminum extrusions with interests in drug discovery and other emerging technologies.

[Top of Page]


TREDEGAR BOARD DECLARES DIVIDEND, SHAREHOLDERS ELECT DIRECTORS

RICHMOND, Va., May 22, 1997 -- The board of directors of Tredegar Industries (NYSE:TG) declared a quarterly dividend of eight cents per share on the company's common stock. The dividend is payable on July 1, 1997, to shareholders of record on June 13, 1997. Earlier today at the company’s annual meeting, Tredegar shareholders elected two new directors to the board: Dr. William M. Gottwald, vice president of corporate strategy and secretary to the executive committee for Albemarle Corporation, and Dr. Richard L. Morrill, president of the University of Richmond. Tredegar’s shareholders also reelected two directors to the board: Norman A. Scher, Tredegar’s executive vice president and chief financial officer, and Austin Brockenbrough, III, managing director of Lowe, Brockenbrough & Tattersall Inc. Tredegar now has 10 people serving on its board of directors. Tredegar Industries is a manufacturer of plastics and aluminum extrusions with interests in drug discovery and other emerging technologies.

[Top of Page]


TREDEGAR’S MOLECUMETICS SUBSIDIARY, ASAHI CHEMICAL TO COLLABORATE ON DRUG RESEARCH

RICHMOND, Va., May 21, 1997 -- Molecumetics Ltd., a Seattle-based subsidiary of Tredegar Industries (NYSE:TG), and Asahi Chemical Industry Co., Ltd., announced today the signing of a multi-year research collaboration aimed at the discovery and development of new drugs for treatment of blood clotting disorders. The joint effort will focus on developing orally active inhibitors of factor VIIa, a key protease in the blood coagulation cascade.

Under the terms of the agreement, Molecumetics will be responsible for the identification and optimization of new drug compounds. Asahi will be responsible for preclinical and clinical development of the compounds in Japan and other Asian countries. Molecumetics will receive research funding, milestone payments based on clinical progress of the compounds, and royalties on sales of products in Japan and Asia. Molecumetics retains all rights to the compounds in the United States and Europe. Additional terms were not disclosed.

Mark Pearson, Molecumetics’ President, said: “We look forward to collaborating with Asahi Chemical on this program. Their commitment to expanding their new drug development business through scientific collaborations with emerging companies like Molecumetics reflects a growing trend toward outsourcing in the pharmaceutical industry. This anti-coagulation program represents only one aspect of Molecumetics’ emerging drug discovery capabilities in the area of protease inhibition. This research approach is a widely recognized way of treating a variety of important diseases, from blood clotting disorders to arthritis and cancer.”

Asahi Chemical Industry Co., Ltd., based in Tokyo, Japan, is a leading supplier of chemicals, petrochemicals, fibers, housing and construction materials, health care products and electronics. With the 1992 merger of Toyo Jozo Co., Ltd., Asahi made a comprehensive entry into the pharmaceutical industry. Intensive work is underway to develop major new pharmaceuticals, particularly for use in the fields of geriatrics and adult diseases, with research and development mainly in the areas of bones, immunology, CNS, and blood/circulatory organs. Asahi’s 1996 revenues totaled 1.2 trillion Japanese yen (approximately $10.4 billion based on recent exchange rates).

Molecumetics is a drug discovery company dedicated to the identification of orally active preclinical lead compounds for clinical development by the pharmaceutical and biotechnology industries. Compounds currently under development at Molecumetics are designed to treat heart disease, blood coagulation disorders, inflammatory diseases such as asthma and arthritis, and cancer.

Tredegar Industries is a Richmond-based manufacturer of plastics and aluminum extrusions with interests in drug discovery and other emerging technologies. Tredegar’s 1996 sales totaled $523.6 million.

[Top of Page]


TREDEGAR REPORTS RECORD RESULTS FROM ONGOING OPERATIONS

RICHMOND, Va., April 11, 1997 -- Driven by higher profits in aluminum extrusions and technology-related investment gains, Tredegar Industries’ (NYSE:TG) first-quarter earnings from ongoing operations were $10,954,000 or 83 cents per share, up from $8,288,000 or 64 cents per share last year. Excluding investment gains, net income from ongoing operations was $9,748,000 or 74 cents per share versus $8,288,000 or 64 cents per share in 1996. Tredegar reported net income of $10,954,000 or 83 cents per share, compared with $16,347,000 or $1.27 per share in 1996. Last year’s results include a nonrecurring after-tax gain of $8.1 million or 63 cents per share related to the divestitures of the company’s molded plastics and materials handling businesses. Results for 1997 include a strong performance in aluminum extrusions, slightly higher profits in plastic films, and lower losses in the company’s technology segment due to sales of equity investments that resulted in an after-tax gain of $1.2 million or nine cents per share. First-quarter sales were $133,345,000, down from $141,387,000 in 1996. The sales decline was due to the inclusion of revenues from divested businesses in last year’s results. Excluding these revenues, first-quarter sales from ongoing operations were $133,345,000, up from $112,744,000 in 1996.

[Top of Page]


TREDEGAR TO CO-LOCATE PRODUCTION FACILITY WITH P&G IN CHINA

RICHMOND, Va., March 27, 1997 -- Tredegar Industries (NYSE:TG) announced plans to open a plastic films manufacturing facility in southeastern China by the end of 1997. The new facility will be located within an existing Procter & Gamble (NYSE:PG) plant near Guangzhou, which is near Hong Kong. Tredegar currently supplies P&G with a variety of plastic films used in disposable personal care products. The primary markets for these products include North America, the Far East, Latin America and Europe. Anthony J. Rinaldi, president of Tredegar Film Products, said: “The establishment of production capacity in China is an important extension of our continuing globalization efforts. Upon completion of the Guangzhou facility, we’ll have on-site manufacturing capacity in each of our major geographic markets. By co-locating this facility with a P&G plant, we can accelerate penetration of a large and growing market while reducing costs and improving service to our major customer.” Tredegar Film Products is a major supplier of embossed and permeable films for disposable personal products. It also produces films for packaging, medical, industrial, agricultural and landscaping markets. In addition to its international facilities, Tredegar Film Products operates six plants and a technical center in the United States.

[Top of Page]


TREDEGAR AGREES TO PURCHASE ALUMINUM PLANT FROM REYNOLDS METALS

RICHMOND, Va., March 7, 1997 -- Tredegar Industries (NYSE:TG) announced that its William L. Bonnell subsidiary has agreed in principle to acquire an aluminum extrusions and fabrication plant in El Campo, Texas, owned by Richmond-based Reynolds Metals Company (NYSE:RLM). Details of the agreement were not disclosed. The proposed acquisition, which is subject to various conditions, is expected to be completed by May 31. The El Campo plant employs 233 people and generated approximately $45 million in sales in 1996. The facility extrudes and fabricates products used primarily in transportation, electrical and consumer durables markets. Tredegar’s Bonnell subsidiary, which had sales of $219 million in 1996, employs 1,300 people at three extrusion plants in Newnan, Ga., Carthage, Tenn., and Kentland, Ind. Bonnell’s primary markets include building and construction, transportation and consumer durables. John D. Gottwald, Tredegar’s president and chief executive officer, said: “We look forward to completing the acquisition of the El Campo plant. It should enable us to penetrate some new markets that are attractive to us from both a geographic and product standpoint.”

[Top of Page]


TREDEGAR BOARD DECLARES DIVIDEND, SETS ANNUAL MEETING DATE

RICHMOND, Va., Feb. 19, 1997 -- The board of directors of Tredegar Industries (NYSE:TG) declared a quarterly dividend of eight cents per share on the company's common stock. The dividend is payable on April 1, 1997, to shareholders of record on March 17, 1997. Tredegar's board also set March 17, 1997, as the record date for the company's annual meeting of shareholders. The meeting will be held on May 22, 1997, at 9:30 a.m. EDT at the Jefferson Hotel in Richmond, Va.

[Top of Page]


TREDEGAR BOARD NOMINATES TWO NEW DIRECTORS

RICHMOND, Va., Feb. 19, 1997 -- The board of directors of Tredegar Industries today nominated Dr. William M. Gottwald and Dr. Richard L. Morrill for election as directors. The nominations will be voted upon at Tredegar’s annual meeting of shareholders on May 22. Bruce C. Gottwald, a director since 1989, will retire from Tredegar’s board on May 22. At that time, if the new nominees are elected, Tredegar’s total board membership will increase from nine to ten.

Dr. Gottwald is vice president of corporate strategy and secretary to the executive committee for Albemarle Corporation. Before joining Albemarle, he served as senior vice president of Ethyl Corporation from 1994 to 1996 and as president of Whitby, Inc., a pharmaceutical subsidiary of Ethyl, from 1989 to 1994. He served as director of pharmaceutical ventures from 1987 to 1989. He joined Ethyl in 1981 and served in various human resources, budget and energy positions prior to heading Ethyl’s pharmaceutical ventures. A native of Richmond, Dr. Gottwald received a B.S. degree in business administration from Washington & Lee University, an M.D. degree from Tulane University and his M.B.A. degree from the University of Richmond. Dr. Gottwald serves on the board of the Community Foundation serving the greater Richmond area and is a former director of Ethyl, Albemarle and First Colony Corporation.

Dr. Morrill has been president of the University of Richmond since 1988. He served as president of Centre College from 1982 to 1988 and was president of Salem College from 1979 to 1982. From 1977 to 1979, Dr. Morrill served as executive assistant to the provost and affiliate professor of religious studies at Pennsylvania State University. From 1968 to 1977, he was associated with Chatham College, serving as an assistant professor of religion, associate professor of religion, and associate provost and assistant to the president. From 1967 to 1968, he was an instructor at Wells College. A native of Hingham, Mass., Dr. Morrill received an A.B. degree in history from Brown University, a B.D. degree in religious thought from Yale University and his Ph.D. in religion from Duke University. He is a director of Central Fidelity Banks, Inc., the Pew Charitable Trusts Civic Entrepreneur Initiative Advisory Board, the Teagle Foundation, the Williamsburg Investment Trust, the Christian Children’s Fund and the World Affairs Council of Greater Richmond. Dr. Morrill is a member of the American Academy of Religion, the American Society of Christian Ethics, the American Association of Higher Education, the Society for Values in Higher Education, the Association for Integrative Studies and the Association for Practical and Professional Ethics.

Bruce C. Gottwald, chairman and chief executive officer of Ethyl Corporation, has served on Tredegar’s board since the company was spun off from Ethyl Corporation in 1989.

[Top of Page]


TREDEGAR REPORTS IMPROVED FOURTH-QUARTER, YEAR-END RESULTS

RICHMOND, Va., Jan. 13, 1997 -- Tredegar Industries (NYSE:TG) reported fourth-quarter net income of $9,280,000 or 70 cents per share, up from $6,908,000 or 53 cents per share in 1995. The increase was driven by record profits in the company’s plastic films business and higher profits in aluminum extrusions. Fourth-quarter sales were $126,408,000 versus $142,734,000 in 1995. Tredegar’s net income in 1996 was $45,035,000 or $3.44 per share, up from $24,053,000 or $1.80 per share in 1995. Full-year results for 1996 include a nonrecurring net gain of $8,479,000 or 65 cents per share related primarily to divestitures. Results for 1995 include a net charge of $41,000, or less than one cent per share, related to nonrecurring items. Total sales in 1996 were $523,551,000, compared with $589,454,000 in 1995. Excluding nonrecurring items, 1996 net income was $36,556,000 or $2.79 per share versus $24,094,000 or $1.80 per share in 1995. These results reflect record profits in Tredegar’s plastics and aluminum businesses and lower losses in its technology segment due to investment gains. Excluding nonrecurring items and investment gains, Tredegar’s 1996 net income was $35,187,000 or $2.69 per share.

The decline in sales for both periods was due to the inclusion of revenues from the company’s Molded Products and Brudi subsidiaries, which were divested in 1996. Excluding these revenues, fourth-quarter sales in 1996 were $126,408,000, up from $115,449,000 in 1995. On a similar basis, annual sales in 1996 were $489,040,000, up from $472,709,000 in 1995.

[Top of Page]


TREDEGAR BOARD RAISES DIVIDEND

RICHMOND, Va., Nov. 20, 1996 -- The board of directors of Tredegar Industries (NYSE:TG) voted today to raise the quarterly cash dividend on the company’s common stock by 33 percent, from six cents to eight cents per share. The dividend is payable on Jan. 1, 1997, to shareholders of record on Dec. 13, 1996.

[Top of Page]


TREDEGAR REPORTS IMPROVED THIRD-QUARTER RESULTS

RICHMOND, Va., Oct. 11, 1996 -- Tredegar Industries (NYSE:TG) reported third-quarter net income of $10,735,000 or 82 cents per share, up from $6,626,000 or 50 cents per share in 1995. Excluding nonrecurring items, net income was $10,315,000 or 79 cents per share versus $6,175,000 or 47 cents per share last year. Third-quarter sales were $129,425,000, down from $145,955,000 last year.

Net income for the first nine months of 1996 was $35,755,000 or $2.74 per share, up from $17,145,000 or $1.27 per share in 1995. Excluding nonrecurring items, year-to-date net income was $27,276,000 or $2.09 per share compared with $17,186,000 or $1.27 per share last year. Sales in the first nine months of 1996 totaled $397,143,000, down from $446,720,000 in 1995.

Tredegar’s third-quarter earnings were driven by continued strength in its core plastics and aluminum extrusions businesses and lower losses in its technology segment, where the sale of an equity investment in Indigo Medical Inc. resulted in an after-tax gain of $1.4 million or 10 cents per share. The decline in sales for both periods was due primarily to the 1996 divestitures of the company’s Molded Products and Brudi subsidiaries.

John D. Gottwald, Tredegar’s president and chief executive officer, said: “The fact that the third quarter is normally a seasonal peak for Tredegar does not fully explain these exceptional results. This time around, it seems everything went our way. Our plastic films business continued its strong performance, and results in aluminum exceeded our most aggressive expectations. The investment gain in our technology segment was icing on the cake. While the accomplishments of our employees never cease to amaze me, this quarter will be hard to top.”

Third-quarter results include an after-tax gain of $1.2 million or nine cents per share related to the sale of a former plastic films manufacturing site in Fremont, Calif. Results for the quarter also include an after-tax charge of $795,000 or six cents per share related to the write-off of excess industrial packaging film capacity. Last year’s third-quarter results include a net after-tax gain of $451,000 or three cents per share related to nonrecurring items.

In addition to third-quarter gains and charges, year-to-date results for 1996 include a net after-tax gain of $8.1 million or 62 cents per share related to divestitures. Year-to-date results for 1995 include a net after-tax gain of $41,000, or less than one cent per share, related to nonrecurring items.

[Top of Page]